Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis - Indian Journal of Dermatology, Venereology and Leprology
PDF) Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
Rapamycin cream may slow ageing in human skin: Study
Home - HYFTOR® Patient Site
Sirolimus API Manufacturers | Suppliers | Drug Master Files (DMF) | CEP | Pharmacompass.com
mTOR inhibitor rapamycin (sirolimus) as a treatment option for tuberous sclerosis - Cfm Oskar Tropitzsch GmbH
Pharmaceutics | Free Full-Text | Mixed Polymeric Micelles for Rapamycin Skin Delivery
IJMS | Free Full-Text | Rapamycin Alleviates 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Aggravated Dermatitis in Mice with Imiquimod-Induced Psoriasis-Like Dermatitis by Inducing Autophagy
About HYFTOR - HYFTOR® Patient Site
Sirolimus Tablets, Siddha Pharmacy, 10 Tablet at Rs 720/stripe in Ahmedabad | ID: 25487857462
PDF) Topical rapamycin (sirolimus) for facial angiofibromas
Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect
Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions - Tu - 2014 - Australasian Journal of Dermatology - Wiley Online Library
Home - HYFTOR® HCP Site
Sirokem Sirolimus Tablets, Kachhela at Rs 333/box in New Delhi | ID: 25117091233
Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect
Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect
Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice | HTML | Acta Dermato-Venereologica
FDA approves Nobelpharma's HYFTOR™ (sirolimus topical gel) 0.2%
Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect
Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma - Indian Journal of Dermatology, Venereology and Leprology
